Document Detail

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).
MedLine Citation:
PMID:  19447387     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: JELIS was a large-scale clinical trial that investigated the effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD). In this paper, the data of patients registered in JELIS were analysed to compare the incidence of CAD between patients with impaired glucose metabolism (IGM) and normoglycemic (NG) patients. The effect of EPA on the incidence of CAD in patients with IGM was also assessed. METHODS: The 18,645 hypercholesterolemic patients registered in JELIS were divided into two groups. One group consisted of patients with IGM (n=4565), which included the patients who had diabetes mellitus and patients who had a fasting plasma glucose of 110mg/dL or higher, either at the time of registration or after 6 months. The other group consisted of NG patients (n=14,080). CAD incidence of the two groups over the average 4.6-year follow-up period was compared, and the effect of EPA was assessed. RESULTS: Compared to NG patients, IGM patients had a significantly higher CAD hazard ratio (1.71 in the non-EPA group and 1.63 in the EPA group). The treatment with EPA resulted in a 22% decrease in the CAD incidence (P=0.048) in IGM patients and an 18% decrease (P=0.062) in NG patients. CONCLUSIONS: It was found that the CAD risk in IGM patients is higher than in NG patients, and that highly purified EPA is very effective in decreasing the incidence of CAD among Japanese IGM patients, even though the intake of fish is high.
Shinichi Oikawa; Mitsuhiro Yokoyama; Hideki Origasa; Masunori Matsuzaki; Yuji Matsuzawa; Yasushi Saito; Yuichi Ishikawa; Jun Sasaki; Hitoshi Hishida; Hiroshige Itakura; Toru Kita; Akira Kitabatake; Noriaki Nakaya; Toshiie Sakata; Kazuyuki Shimada; Kunio Shirato;
Related Documents :
10738357 - Analysis of trials of surgery vs angioplasty in myocardial revascularization.
4014037 - Factors associated with progression of coronary artery disease in patients with normal ...
11552207 - Detection and treatment of coronary artery disease in liver transplant candidates.
8015147 - Diagnostic value of transient dilatation of the left ventricle in negative dipyridamole...
23272527 - Importance of posture assessment in ankylosing spondylitis. preliminary study.
19731237 - Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatoc...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-04-05
Journal Detail:
Title:  Atherosclerosis     Volume:  206     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-05     Completed Date:  2009-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  535-9     Citation Subset:  IM    
Nippon Medical School, Department of Medicine, 1-1-5 Sendagi, Bunkyoku, Tokyo 113-8603, Japan.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Artery Disease / drug therapy*,  epidemiology,  prevention & control*
Diabetes Mellitus / drug therapy*
Eicosapentaenoic Acid / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / blood,  complications,  drug therapy*,  epidemiology
Japan / epidemiology
Middle Aged
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 1553-41-9/Eicosapentaenoic Acid
Comment In:
Curr Atheroscler Rep. 2009 Nov;11(6):399-400   [PMID:  19852879 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sound to meaning correspondences facilitate word learning.
Next Document:  Modulation of phenotypic expression of APOA5 Q97X and L242P mutations.